Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Injectable buprenorphine formulation

a buprenorphine and injection technology, applied in the direction of nervous disorder, non-active ingredients of oil/fat/waxes, drug compositions, etc., can solve the problems of debilitating and unpleasant withdrawal, affecting the release of buprenorphine, and causing serious side effects. achieve the effect of favorable release profiles

Inactive Publication Date: 2018-01-18
CAMURUS AB
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent discusses the development of highly effective controlled-release formulations for active agents such as buprenorphine. These formulations use lipid mixtures that change phase upon injection, resulting in a slow-release effect. After a few months of treatment, the average concentration of buprenorphine in the body remains within a therapeutic range, providing improved effectiveness and a better experience for the subject.

Problems solved by technology

Concentrations below the functional window are typically inactive or less effective and concentrations above the functional window have the potential to cause serious side-effects.
Insufficient dose, especially in subject accustomed to opioids, can cause debilitating and unpleasant withdrawal symptoms while excessive dose cause euphoria, reinforcement of dependence and ultimately potentially fatal respiratory depression.
Such formulations may be ineffective or inefficient at low concentrations of buprenorphine but provide a much more desirable release profile when the buprenorphine concentration is held above around 16% by weight.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injectable buprenorphine formulation
  • Injectable buprenorphine formulation
  • Injectable buprenorphine formulation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Composition Comprising Buprenorphine Base, Sesame Oil and N-Methyl Pyrrolidone (NMP)

[0094]The composition according to Table 1 was prepared by weighing 2.03 g buprenorphine base, 1.80 g NMP and 2.17 g of Sesame oil in a 10 mL injection glass vial. The vial was closed with Flurotec®-coated rubber stopper and aluminum crimp cap followed by end-over-end rotation mixing at ambient room temperature until a liquid, transparent and homogenous formulation was obtained. The formulation was finally subjected to filtration through a sterile 0.22 μm Millex®-GV membrane (Millipore) under nitrogen pressure.

TABLE 1Composition of buprenorphine, triglyceride and solvent (wt %)FormulationBuprenorphineSesame oilNMPA133.836.230.0NMP = N-methyl pyrrolidone

example 2

Compositions Comprising Buprenorphine Base, Triglycerides and Solvents

[0095]The compositions according to Table 2 are prepared by weighing the required amounts of buprenorphine base, triglyceride and solvent in 4 mL injection glass vials. The vials are closed with Flurotec®-coated rubber stoppers and aluminum crimp caps followed by end-over-end rotation mixing at ambient room temperature.

TABLE 2Composition of buprenorphine, triglyceride and solvent (wt %)SesameCastorFormulationBuprenorphineoiloilMCTNMPDMSOB133.8—36.2——30.0B225.4—44.6——30.0B316.9—63.1——20.0B440.0—20.0——40.0B525.444.6——30.0—B616.963.1——20.0—B740.020.0——40.0—B833.8——36.230.0—B925.4——44.630.0—B1016.9——63.120.0—B1140.0——20.040.0—DMSO = Dimethyl sulphoxideNMP = N-methyl pyrrolidoneMCT = Medium Chain Triglycerides (e.g. Labrafac Lipophile WL 1349, Gattefossé, France)

example 3

Composition Comprising Low Drug Load Buprenorphine Base, Triglyceride and Solvent

[0096]The composition according to Table 3 was prepared by weighing 0.0424 g buprenorphine base, 0.400 g Ethanol and 3.558 g of Castor oil in a 10 mL injection glass vial. The vial was closed with Flurotec®-coated rubber stopper and aluminum crimp cap followed by end-over-end rotation mixing at ambient room temperature until a liquid, transparent and homogenous formulation was obtained. The formulation was finally subjected to filtration through a sterile 0.22 μm Millex-GP membrane (Millipore) under nitrogen pressure.

TABLE 3Composition of buprenorphine, triglyceride and solvent (wt %)FormulationBuprenorphineCastor oilEtOHC11.0688.9410.00EtOH = Ethanol

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention provides an injectable liquid formulation with controlled release comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and / or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and / or cocaine withdrawal by injecting such a liquid composition.

Description

[0001]The present invention relates to injectable formulations of opioid agonists such as buprenorphine. In particular the invention relates to injectable lipid formulations having the ability to form controlled-release compositions upon injection.BACKGROUND TO THE INVENTION[0002]Many active pharmaceutical ingredients and other bioactive agents exhibit a functional concentration window in vivo such that blood plasma concentrations of active agent in particular range will provide the desired effect. Concentrations below the functional window are typically inactive or less effective and concentrations above the functional window have the potential to cause serious side-effects.[0003]Opioid agonists are a prime example of pharmaceutical agents for which adherence to an effective functional window, which may vary significantly between patients and over time, is of great importance. Opioids are indicated in many conditions including treatment of pain and in various forms for treatment an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K47/20A61K31/485A61K47/12A61K47/44A61K47/22
CPCA61K9/0019A61K47/44A61K47/22A61K31/485A61K47/20A61K47/12A61K9/0002A61K9/0024A61K47/14A61P25/04A61P25/36A61P29/00A61K9/08
Inventor TIBERG, FREDRIKJOHNSSON, MARKUSHARWIGSSON, IAN
Owner CAMURUS AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com